Numeric Investors’s Neurocrine Biosciences NBIX Stock Holding History

Numeric Investors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-12,600	Closed	-$580K	–	1140
2017 Q2	$580K	Buy	+12,600	New	+$611K	0.01%	787
2016 Q2	–	Sell	-11,800	Closed	-$467K	–	1112
2016 Q1	$467K	Sell	11,800 -1,800	-13%	-$71.4K	﹤0.01%	729
2015 Q4	$769K	Buy	+13,600	New	+$691K	0.01%	639
2014 Q1	–	Sell	-12,200	Closed	-$114K	–	869
2013 Q4	$114K	Buy	+12,200	New	+$119K	﹤0.01%	750
2013 Q3	–	Sell	-12,100	Closed	-$162K	–	835
2013 Q2	$162K	Buy	+12,100	New	+$149K	﹤0.01%	735

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Numeric Investors's NBIX Position: Q3 2017 in Review

Numeric Investors sold out of Neurocrine Biosciences (NBIX) in Q3 2017, closing a stake of 12,600 shares — an estimated $580K sold.

Numeric Investors first reported a position in NBIX in Q2 2013 and held it in 5 quarters. The position peaked at $769K in Q4 2015. 223 funds tracked by Wall St. Rank hold NBIX as of Q3 2017.

Numeric Investors reported no remaining Neurocrine Biosciences position as of Q3 2017 after selling out during the quarter.
Numeric Investors sold 12,600 Neurocrine Biosciences shares in Q3 2017, an estimated $580K.
Numeric Investors first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 5 quarters.
Numeric Investors's Neurocrine Biosciences position peaked at $769K in Q4 2015.
223 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2017.

Based on Numeric Investors's 13F filing for Q3 2017, filed 14 Nov 2017.